May 25th 2022
Closing out their discussion on the management of prostate cancer, panelists consider remaining unmet needs and future directions in care.
Reflections on results of the VISION trial, which utilized 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
May 19th 2022
Highlighting ongoing clinical trials in prostate cancer, experts share practical advice on optimal treatment strategies for community physicians.
May 18th 2022
A broader perspective on the management of bone and visceral metastases in metastatic CRPC given the current treatment landscape.
Shifting their focus to 177Lu-PSMA-617 in metastatic CRPC, expert panelists consider its role in sequencing therapy and managing bone metastases.
May 12th 2022
Before closing out their discussion, experts review novel targeted agents under investigation in metastatic CRPC.
Experts share insight on the greatest unmet needs in treating patients with metastatic castration-resistant prostate cancer.
May 11th 2022
A brief discussion on how to select and apply novel imaging strategies in patients with metastatic castration-resistant prostate cancer.
Shared insight on the role of imaging as a phenotypic biomarker in patients being treated for metastatic castration-resistant prostate cancer.
May 5th 2022
Andrew J. Armstrong, MD, MSc, breaks down ongoing prostate cancer clinical trials looking at targeted radioligand therapies.
Oliver Sartor, MD, considers the respective roles of Lu-PSMA-617 and radium-223 as radiotherapy in the setting of mCRPC.
May 4th 2022
Expert perspectives on how DNA alterations may inform the selection and use of PARP inhibitors in metastatic CRPC.
A broad overview of the armamentarium for metastatic CRPC followed by detailed discussion on the role of PARP inhibitors in this setting.
April 28th 2022
Expert perspectives on where Lu-PSMA-617 therapy may fit into the treatment paradigm for metastatic castration-resistant prostate cancer.
A comprehensive review of the design and results of VISION, which analyzed Lu-PSMA-617 therapy in patients with mCRPC.
April 27th 2022
Comprehensive insight on results from the ARASENS trial and how panelists will be incorporating what was learned into real-world clinical practice.
Focusing on treatment selection factors in metastatic HSPC, panelists consider how the ARASENS trial redefined treatment approaches.
April 21st 2022
Expert Scott Tagawa, MD, MS, FACP, details the role of radium-223 in treating metastatic CRPC and highlights real-world experiences.
Shared insight on the key factors that play into the selection of therapy for patients with metastatic castration-resistant prostate cancer.
April 20th 2022
Shared insight on the role of micronized abiraterone in metastatic HSPC and how it may be utilized in practice.